Maze Therapeutics (MAZE) vs Vir Biotechnology (VIR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Vir Biotechnology (VIR) has outperformed Maze Therapeutics (MAZE) over the past year, gaining 47.7% versus a loss of 13.5%. Maze Therapeutics is the larger company by market cap ($1.72 billion vs $1.56 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MAZE | VIR |
|---|---|---|
| Share price | $31.37 | $8.39 |
| Market cap | $1.72B | $1.56B |
| 1-day change | -3.27% | -5.41% |
| YTD return | -24.28% | +39.14% |
| 1-year return | -13.49% | +47.71% |
| 5-year return | — | -76.69% |
| EPS (TTM) | $-2.62 | $-1.18 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $68.56M |
| Revenue growth (YoY) | — | -7.61% |
| Net income (latest FY) | $-131.12M | $-437.99M |
| Gross margin | — | 99.96% |
| Operating margin | — | -699.18% |
| Net margin | — | -638.87% |
| 52-week high | $53.65 | $14.38 |
| 52-week low | $21.95 | $5.45 |
| Distance from 52-week high | -41.53% | -41.66% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +99.11% | +178.67% |
| Average volume | 737.14K | 2.45M |
| Shares outstanding | 54.68M | 186.27M |
| Employees | 141 | 367 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- VIR has outperformed MAZE by 61.2 percentage points over the past year.
About Maze Therapeutics
MAZE stock →Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of kidney and metabolic diseases in the United States. Its lead programs include MZE829, an oral small molecule inhibitor of apolipoprotein L1, or APOL1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor that is in phase II ready clinical trial for the treatment of phenylketonuria and chronic kidney disease.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 141 employees
About Vir Biotechnology
VIR stock →Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally. Its clinical development pipeline consists of product investigational therapies targeting hepatitis delta virus (HDV) and other solid tumors.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 367 employees
MAZE vs VIR FAQ
Which is bigger, Maze Therapeutics or Vir Biotechnology?
Maze Therapeutics (MAZE) is larger, with a market capitalization of $1.72B compared with $1.56B for Vir Biotechnology (VIR).
Which stock has performed better over the past year, MAZE or VIR?
VIR returned +47.71% over the past 12 months, compared with -13.49% for MAZE (price return, excluding dividends). Past performance does not predict future results.
Are Maze Therapeutics and Vir Biotechnology in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.